{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:19:24Z","timestamp":1777861164734,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["1151479"],"award-info":[{"award-number":["1151479"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["1158763"],"award-info":[{"award-number":["1158763"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","award":["DS-18-01"],"award-info":[{"award-number":["DS-18-01"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.lungcan.2022.01.024","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T11:36:31Z","timestamp":1643888191000},"page":"40-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"166","author":[{"given":"Monica","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig R.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sallie-Anne","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Simes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.lungcan.2022.01.024_b0005","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Eng. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2022.01.024_b0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10183","key":"10.1016\/j.lungcan.2022.01.024_b0015","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.lungcan.2022.01.024_b0020","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2022.01.024_b0025","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.lungcan.2022.01.024_b0030","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.lungcan.2022.01.024_b0035","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2022.01.024_b0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0798","article-title":"Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials","volume":"4","author":"O\u2019Connor","year":"2018","journal-title":"JAMA Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2022.01.024_b0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.10009","article-title":"FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration","volume":"35","author":"Singh","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2022.01.024_b0050","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/cncr.21907","article-title":"Generalizability of cancer clinical trial results","volume":"106","author":"Elting","year":"2006","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2022.01.024_b0055","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.2003.08.010","article-title":"Participation of patients 65 years of age or older in cancer clinical trials","volume":"21","author":"Lewis","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2022.01.024_b0060","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","article-title":"Association of patient comorbid conditions with cancer clinical trial participation","volume":"5","author":"Unger","year":"2019","journal-title":"JAMA oncology"},{"issue":"10","key":"10.1016\/j.lungcan.2022.01.024_b0065","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jtho.2017.07.020","article-title":"Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity","volume":"12","author":"Garcia","year":"2017","journal-title":"J. Thoracic Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2022.01.024_b0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2407-9-130","article-title":"Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials","volume":"9","author":"Vardy","year":"2009","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2022.01.024_b0075","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/annonc\/mdr443","article-title":"The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials","volume":"23","author":"Clarey","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.024_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2018.05.014","article-title":"Clinical characteristics and prognosis of patients with advanced non-small cell lung cancer who are ineligible for clinical trials","author":"Kawachi","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2022.01.024_b0085","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/1759-7714.12641","article-title":"Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer","volume":"9","author":"Yoo","year":"2018","journal-title":"Thoracic Cancer"},{"issue":"33","key":"10.1016\/j.lungcan.2022.01.024_b0090","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical oncology and friends of cancer research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.024_b0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cct.2018.01.003","article-title":"Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative","volume":"66","author":"Huang","year":"2018","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.lungcan.2022.01.024_b0100","doi-asserted-by":"crossref","DOI":"10.1200\/OP.21.00108","article-title":"Role of Immune Checkpoint Inhibitors in Understudied Populations","author":"Kadakia","year":"2021","journal-title":"JCO Oncol. Practice"},{"issue":"11","key":"10.1016\/j.lungcan.2022.01.024_b0105","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review","volume":"297","author":"Van Spall","year":"2007","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.lungcan.2022.01.024_b0110","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non\u2013small-cell lung cancer with PD-L1 Tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2022.01.024_b0115","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/j.jtho.2021.01.143","article-title":"KEYNOTE-042 3-year survival update: 1L pembrolizumab vs platinum-based chemotherapy for PD-L1+ locally advanced\/metastatic NSCLC","volume":"16","author":"Cho","year":"2021","journal-title":"J. Thoracic Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2022.01.024_b0120","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2022.01.024_b0125","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2022.01.024_b0130","author":"Simes","year":"2020","journal-title":"Embedding Research (and evidence) in Cancer Healthcare (EnRICH) - Program Protocol"},{"issue":"2","key":"10.1016\/j.lungcan.2022.01.024_b0135","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non\u2013small cell lung cancer\u2014a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2022.01.024_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102031","article-title":"Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer","volume":"87","author":"Pasello","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"22","key":"10.1016\/j.lungcan.2022.01.024_b0145","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1002\/cncr.32383","article-title":"Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non\u2013small cell lung cancer","volume":"125","author":"Khozin","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2022.01.024_b0150","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1200\/CCI.20.00084","article-title":"Real-world outcomes for patients treated with immune checkpoint inhibitors in the veterans affairs system","volume":"4","author":"La","year":"2020","journal-title":"JCO Clin. Cancer Inform."},{"key":"10.1016\/j.lungcan.2022.01.024_b0155","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2021.04.007","article-title":"Real-world outcomes of immunotherapy\u2013based regimens in first-line advanced non-small cell lung cancer","volume":"156","author":"Waterhouse","year":"2021","journal-title":"Lung Cancer"},{"issue":"15","key":"10.1016\/j.lungcan.2022.01.024_b0160","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1200\/JCO.19.02035","article-title":"Informing patients about expected outcomes: the efficacy-effectiveness gap","volume":"38","author":"Templeton","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.024_b0165","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1200\/CCI.21.00042","article-title":"Augmenting real-world data through modeling key clinical trial eligibility criteria: an example of patients with non\u2013small-cell lung cancer treated with pembrolizumab","volume":"5","author":"Jemielita","year":"2021","journal-title":"JCO Clin. Cancer Inform."},{"issue":"6","key":"10.1016\/j.lungcan.2022.01.024_b0170","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jgo.2021.02.003","article-title":"Are clinical trial eligibility criteria representative of older patients with lung cancer? A population-based data linkage study","volume":"12","author":"Tang","year":"2021","journal-title":"J. Geriatr. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2022.01.024_b0175","doi-asserted-by":"crossref","first-page":"dju302","DOI":"10.1093\/jnci\/dju302","article-title":"Impact of prior cancer on eligibility for lung cancer clinical trials","volume":"106","author":"Gerber","year":"2014","journal-title":"J. Natl Cancer Inst."},{"issue":"4","key":"10.1016\/j.lungcan.2022.01.024_b0180","doi-asserted-by":"crossref","first-page":"djv002","DOI":"10.1093\/jnci\/djv002","article-title":"Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual","volume":"107","author":"Laccetti","year":"2015","journal-title":"J. Natl Cancer Inst."},{"issue":"33","key":"10.1016\/j.lungcan.2022.01.024_b0185","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology-friends of cancer research organ dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group","volume":"35","author":"Lichtman","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2022.01.024_b0190","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection","volume":"7","author":"Shah","year":"2019","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.lungcan.2022.01.024_b0195","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2022.01.024_b0200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","article-title":"Prevalence of poor performance status in lung cancer patients: implications for research","volume":"3","author":"Lilenbaum","year":"2008","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2022.01.024_b0205","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2020.04.027","article-title":"ECOG performance status \u22652 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors\u2014A systematic review and meta-analysis of real world data","volume":"145","author":"Dall\u2019Olio","year":"2020","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2022.01.024_b0210","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jtho.2019.05.010","article-title":"Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153)","volume":"14","author":"Spigel","year":"2019","journal-title":"J. Thoracic Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2022.01.024_b0215","doi-asserted-by":"crossref","first-page":"e001865","DOI":"10.1136\/jitc-2020-001865","article-title":"Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer","volume":"9","author":"Ardizzoni","year":"2021","journal-title":"J. ImmunoTher. Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222000393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222000393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:05:28Z","timestamp":1777518328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222000393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":43,"alternative-id":["S0169500222000393"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.01.024","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}